Health Archive » August, 2011

Health - August, 2011

243 articles

• Baxter Sues Teva Over Propofol Indemnity Pact
• CareFusion Hits Hospira With Infusion System IP Suit
• FDA Urged To Ban J&J, Allergan Breast Implants
• Merck, Others Can't Dodge Jury's Chromium Verdict
• 2 Classen Patents Pass Bilski Test: Fed. Circ.
• Urology Group Settles Pa.'s Monopoly Claims
• Rejected Individual Deals Don't Doom Classes: 3rd Circ.
• Merck Sues Ky. AG For Using Private Firm In Vioxx Suit
• Medicare Revision Doesn't Bar Contract Suit: Fed. Circ.
• Tainted Avastin Caused Eye Infections: FDA
• Judge Affirms Decision To Allow Coventry Fraud Action
• Acella Loses Bid To Nix False Ad Suit Over Vitamin Labels
• ACA Adaptation: Benefits And Coverage Summaries
• NLRB Reverses Bush-Era Ruling Over Union Challenges
• LabCorp Reaches $49.5M Deal To End Medi-Cal Fraud Suit
• Merck Gets Bellwether Suit Slashed In Fosamax MDL
• Ex-Fed. Circ. Chief, Others Blast Patent Reform
• Bankrupt Drug Tester Can Avoid Inova Lien: 8th Circ.
• Avanir Targets Wockhardt In Nuedexta Patent Blitz
• Ex-Pharma Holdings Execs Shell Out $2M To End Fraud Suit
• Drug Co. Seeks Quick Win On False Ad Claims In IP Suit
• US Should Create Fund For Research Injuries: Report
• Pfizer Settles Lipitor Patent Suit Against Dr. Reddy's
• Bristol-Myers Hit With IP Suit Over Data Encryption
• Hospital Can Bar 'Inflammatory' Pro-Union Gear: Judge
• Shire Patent Suit Over Generic Intuniv Survives
• Mylan Loses Bid To Dismiss MS Drug Patent Suit
• RSUI Drops Appeal In Copyright Suit Coverage Dispute
• Cedars-Sinai Can't Shake Doc's $4.7M Retaliation Award
• 3M Stakes New Forum In BacLite Blackmail Suit
• 11th Circ. Vacates Sanctions Against US In Shaygan Case
• Baxter Workers Win Class Cert. In Meal Break Action
• Group Seeks Faster Label Updates For Generics Makers
• Allergan Sues Sandoz Over Lumigan Patents
• 2011 Attorney Marketing: Where Do You Stand?
• CVS Asks High Court To Put W.Va. Drug Suit In Fed. Court
• Children's Hospital Settles Infant Care Antitrust Suit
• Doc Says Tampa Firm Cut Him Out Of Genzyme Qui Tam
• US, State Pre-Existing Condition Plans See Low Enrollment
• Mylan's Generic Oracea Infringes Galderma IP: Judge
• Amgen Can't Dodge Kickback Claims In Aranesp Suit
• Merck's $32M Damages Nixed In Vioxx Wrongful Death Suit
• Husband Admits He Lied About Ponzi Fugitive's Location
• Argentum To Pay Noble $1M In Fees In Dressing IP Fight
• Pregnant Worker Can't Claim Disability Bias: 7th Circ.
• Nonprofits Escape Calif. Junk Insurance Claims
• Shuttered Drug Co. Recalls Surgical Antiseptics
• Vention Medical Picks Up Tubing Maker Ansamed
• UBS Didn't Earn $7.8M Transaction Fee: Stem Cell Co.
• Alcon Sues Apotex Over Generic Allergy Spray
• 2nd Circ. Nixes Wells Fargo Credit Agreement Row
• Teva Nixes Suit Against Apotex Over Parkinson's Drug
• Hansen Medical Securities Fraud Action Nixed
• Hologic Workers Win Initial Cert. In Overtime Action
• Medtronic Insulin Pumps Open To Cyberattack: Hacker
• Fed. Circ. Upholds Unigene Win Over Fortical Patents
• Foley Snags McDermott M&A Pro For Health Care Group
• UK Seeks Deeper Antitrust Review Of Stericycle Deal
• Balancing The Health Care Reform Debate
• Ex-National Century CEO Takes Convictions To High Court
• Michael Best Adds Polsinelli IP Attys In Chicago
• Kirkland Reps Baxter International In $380M Baxa Buy
• No Government Intervention? No FCA Merit In 5th Circ.
• Class Cert. Granted In Boiron False Advertising Suit
• Mass. Asks To Join Healthpoint Fraud Suit Over Xenaderm
• US Sues To Freeze Assets In Weight Loss Clinic Fraud Case
• A Hindsight-Averse Application Of Lead Compound Case Law
• Sanofi Unit Snaps Up Indian OTC Business For $109M
• Par, UCB Pharma Settle Keppra Patent Fight
• High Doses Of Celexa May Cause Heart Disorder: FDA
• 5th Circ. Gives Stryker Knee Implant Action New Life
• Investor Hits Advanced Cell With $12M Stock Fraud Suit
• CAE Adds Medical Simulator Co. METI For $130M
• Orrick, Arent Rep Par Pharma In $410M Anchen Buy
• Judge Strips Ethypharm's Antitrust Suit Over TriCor IP
• 6th Circ. OKs 7-Year Sentence For NCFE Witness Bribe
• Contractor Settles Civil Suit Over Fake Drug Test Claims
• NY Docs Billed $23M In No-Fault Insurance Fraud: Geico
• GSK Drug Reps Ask High Court To Review OT Exemption
• Fed. Circ. Won't Revive Novartis Hemophilia Drug IP Suit
• Novartis Settles Famvir Patent Dispute
• Beckman Must Boost Lab Device Quality Practices: FDA
• Masimo Targets Philips In Latest Blood Device IP Suit
• Lessons From Stanford
• Judge Says Ventas Can Collect $102M Award From HCP
• Allergan Triumphs In Suits Over Generic Combigan
• Ex-Head Of Drug Testing Co. Cops To Billing Fraud
• St. John's Faces Contract Suit Over Eye Research Deal
• 10 States, DC Defend Health Care Law In 8th Circ.
• Walgreen Nabs Ex-United Air Top Atty
• CDI Seeks Sanctions Against Ex-Employee In FCA Suit
• Troubleshooting ACO Antitrust Enforcement
• Cravath Reps Aptuit In $410M Deal With Catalent
• CVS Agrees To Pay $2M Over Misleading Pricing Ads
• Masimo Hit With Oximetry Device IP Suit
• FTC Loses Lundbeck Baby Meds Fight Before 8th Circ.
• Cadence Sues Exela, Paddock To Block Generic Ofirmev
• Blackstone, Goldman Escape Junk Insurance Case
• State Quota Violates Commerce Clause, Not Sherman Act
• Novartis, Apotex Resolve Suit Over Myfortic Patents
• Schering Says Judge Missed Key Facts In Sales Rep OT Suit
• Damages Only — No 'Full Billed Charges' Allowed
• Class Status Sought In Express Scripts-Medco Deal Suit
• Blank Rome Scores IP Pro From Vorys
• Overhauling The 510(k) Process
• Smith & Nephew Hit With Knee Implant Patent Suit
• Ex-Lab Owner Admits To Selling Unapproved Stem Cells
• KVK Accuses Sunrise Of Stealing Employees, Trade Secrets
• Sandoz Wants Novo's Prandin Patent Ruled Invalid Again
• Allergan Sues Again To Block Generic Latisse
• Judge OKs Medical Monitoring For DuPont Plaintiffs
• Personal Injury Plaintiffs Can't Recoup Fee Discounts: Court
• Forest Labs Defeats Icahn In Proxy Fight
• Laying Claim To DNA
• 2nd Circ. Rejects NYC Bid To Undo Insurance Merger
• Jury Hands Win To Breg In 1st Pain Pump Trial
• Endo Strikes Mylan With Suit Over Generic Frova
• HHS Unveils Standardized Health Insurance Forms
• Insurers Correctly Defined Cancer Coverage: Judge
• Panel Backs Most Allegra Ad Claims
• Pfizer Sues To Block Generic Lipitor
• NM Hospital Seeks Ch. 11 As Malpractice Suits Loom
• P&G Denture Cream Suits To Stay Put In MDL
• Pa. Hospital Group Sued Over Meal Break Policy
• Darvocet, Darvon Heart Risk Suits Consolidated
• Baxter Says Fresenius Owes $20M Over Dialysis Patent
• Medicis, Nycomed Settle Vanos Patent Dispute
• Google, Others Back Fed. Circ. Joint Infringement Rulings
• Abbott Targets Teva Over Latest Simcor ANDA
• Personalized Medicine, Patents And The Supreme Court
• Implications Of Blanco V. Bath Iron Works
• Abbott Hit With 2 Suits Over Depakote Birth Defects
• Indirect Purchasers Certified In Wellbutrin Antitrust Suit
• Judge Boots Investor Class Action Over Feraheme Risks
• Pfizer Sues Merck, Schering Unit Over Lipitor Look-Alike
• FDA Unveils New Standards For Premarket Device Studies
• Investors Target BioMimetic Over Bone Graft Statements
• Class Certified In Cigna Autism Treatment Suit
• Pfizer's Viagra Patent Survives Teva Challenge
• Applying Section 1 To Hospital Peer Review Decisions
• Dentists Win Class Cert. In Nobel Biocare Implant Suit
• Sanofi Says Sales Rep OT Suit Exploits FLSA Loophole
• Ex-FrontPoint Trader Cops To Receiving Insider Tips
• Ex-MediSys CEO Made Up Lawmakers' Consulting Gigs: US
• Anti-Health Care Reform Measure To Be On Ohio Ballot
• Fed. Circ. Denies Eon's Fee Bid In Skelaxin IP Case
• CDI Gets Stark Act Claim Tossed In Medicare FCA Suit
• Body Science Aims To Ax Winston & Strawn From IP Case
• 9th Circ. Affirms Dismissal Of Health Care Law Suit
• Health Law's Mandate Unconstitutional: 11th Circ.
• 6th Circ. Nixes Class Cert. In Blue Cross ERISA Suit
• Stryker Unit Dodges Zimmer's Sanctions Bid
• Funding Regional Insurance Programs
• AstraZeneca Settles Idaho's AWP Suit For $2.5M
• St. Vincent's $34M Sale Of Nursing Home OK'd
• FLSA Cert. Process Challenged In Light Of Dukes
• Insurance Overpayment Suit Belongs In State Court: Judge
• GSK Wins False Patent Marking Suit Over Citrucel
• Avanir Sues Par, Actavis To Block Generic Nuedexta
• Inside Sorrell V. IMS Health
• Legal Implications Of New Cancer Causation Theories
• Ex-FrontPoint Trader Ends $30M SEC Insider Trading Suit
• EFF Asks Fed. Circ. To Deny Akamai, McKesson IP Claims
• Bayer, Lilly False Ad Row Over Pet Meds To Stay In NY
• Elan Beats Investor Fraud Claims Over Drug Prospects
• Vioxx Judge Reallocates $315M Counsel Award
• 7th Circ. Nixes CUNA Sick Leave Action
• The Skinny On Texas Senate Bill 7
• Lilly, Hospira Settle Gemzar Patent Fight
• S&N Relator Seeks Sales Docs For Non-US Goods
• Pfizer Can't Shake Investor Suit Over Off-Label Marketing
• EU Patent Decision Admissible In Yaz Row, Bayer Says
• J&J Cuts Deal With US Over Risperdal Marketing Fraud
• Italy Hits Toshiba Unit, Others With €5.5M Antitrust Fine
• JPMorgan Let Health Facility Boss Steal $2M, Suit Claims
• Cooley Snags 3 Life Sciences Partners From Seed IP
• Insurers' Rescission Claim Survives In Heparin Suit
• Caliper, Carestream Settle Animal Imaging IP Row
• Wyeth, Sandoz Lay Down Swords In Effexor Patent Row
• Most Claims Stand In Securities Suit Over Vioxx Risks
• Zimmer Knee Implant Actions Merged Into MDL
• Abbott Fights $3.5M Verdict In GSK Suit Over Norvir
• Forest Decision Does Little To Remove Exclusion Threat
• Canadian Class Certified In Suit Over Wyeth's Premarin
• US Probes Merck's Marketing Of 3 Drugs
• HHS Wants Input On Metadata Standards
• Teva Sued Over Generic HIV Drug
• Clinic's Unsupervised Heart Tests Violated FCA: Suit
• FTC Says NY Pharmacy Choice Bill Could Curb Competition
• Emdeon Investor Fights $3B Blackstone Buyout
• Pozen Wins Injunction On Generic Treximet
• Ex-Schering Sales Reps Prevail In FLSA Suit
• Hogan Lovells Snags Ex-Medtronic Atty With FDA Chops
• 1st Circ. Tosses Boston Scientific Securities Fraud Action
• Brigham And Women's Hospital Says It Lost Patient Info
• 5th Circ. Nixes Relator From McKesson Kickbacks Case
• Ill. Agency Can't Nix Health Plan Contract Freeze
• US Ends Bid To Oust Forest Labs CEO Solomon
• Canada Links Merck Drugs To Male Breast Cancer
• Health Care Competition: Beware The Middleman
• Ex-Orioles Player Settles Insider Trading Suit For $2.5M
• Ferring, Aventis Reach $20M Deal In DDAVP Antitrust Suit
• Ropes & Gray Reps Blackstone In $3B Emdeon Buyout
• Mayer Brown Reps DeVry In $235M Medical School Deal
• Illumina Asks Fed. Circ. To Revive Affymetrix IP Suit
• AstraZeneca Targets Hetero Over Nexium ANDA
• Surviving The 'Magic Microscope' Test
• Hospital Group Blasts HHS' Call For Access Reports
• Allied Shareholder Tries To Halt $175M Saga Deal
• Forest Labs Told To Turn Over Docs On CEO To Icahn
• 3rd Circ. Nixes Doctors' Challenge To Health Care Law
• Prescription Confidentiality Law And The Privacy Debate
• Baker Donelson Adds Ex-Bayer CropScience Patent Head
• High-Dose Diflucan May Cause Birth Defects: FDA
• Dozens Of Health Insurers Sued Over Settlement Liens
• Watchdog Attacks FDA Over Expert Conflicts Policy
• 8th Circ. Revives KV Antifungal Cream Trade Secrets Row
• 10th Circ. Revives Prozac Murder-Suicide Suit
• KemPharm Exec Can't Dodge Shire's Contract Claims
• Omnicom Courts Big Pharma With Synergy Deal
• WebMD Accused Of Hiding Ad Woes Before Stock Plunge
• Detecting Waste And Abuse In Health Care Spending
• Chinese Reverse Merger Co. Hyped 'Worthless' Stock: Suit
• Takeda Accused Of Hiding Diabetes Drug's Cancer Link
• Judge Trims Boehringer Sales Reps' OT Class Action
• Health Plan Cos. Take $2.4M Hit In Marketing Fraud Case
• 8th Circ. Denies 3rd Look At Catheter Antitrust Suit
• US Oncology Debtholders Seek $40M From McKesson Tie-Up
• Feds Fail To Keep FCA Docs Sealed In Omnicare Case
• Immunosyn Execs Hit With $20M Insider Trading Suit
• Fed. Circ. Sides With GSK, Others In Argatroban IP Row
• Gilead Tries To Nix Whistleblower's Retaliation Suit
• US Says States Should Have Final Say On Insurance Rates
• Cantel Expands GI Capabilities With $100M Byrne Deal
• FMC To Shell Out $2.1B For Dialysis Cos.
• Pfizer Unit Wants $65M More For Asbestos Ch. 11
• Hospital Wants More In $3.5M Sex Abuse Coverage Suit
• Mass. Sues J&J Unit Over Risperdal Off-Label Marketing
• Horvitz & Levy Sued Over Missed Deadline In Firing Suit
• Suit Says Zynex Directors' Deception Inflated Stock
• Pharmacies Fight $29B Express Scripts, Medco Deal
• Insurers Must Cover Birth Control At No Cost: HHS
• Is The Medical Device Review System Flawed?